Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 4—April 2015

Prevalence of Hepatitis E Virus Antibodies, Israel, 2009–2010

Orna Mor, Ravit Bassal, Michal Michaeli, Marina Wax, Daniela Ram, Oranit Cohen-Ezra, Dani Cohen, Ella Mendelson, Ziv Ben-Ari, and Tamy Shohat
Author affiliations: Central Virology Laboratory, Ministry of Health, Ramat-Gan, Israel (O. Mor, M. Michaeli, M. Wax, D. Ram, E. Mendelson); Israel Center for Disease Control, Ministry of Health, Ramat-Gan (R. Bassal, T. Shohat); Sheba Medical Center, Ramat-Gan (O. Cohen-Ezra, Z. Ben-Ari); Tel-Aviv University, Tel-Aviv, Israel (D. Cohen, E. Mendelson, T. Shohat)

Cite This Article


We investigated prevalence of hepatitis E virus in a sample of the population of Israel. The overall seroprevalence of antibodies to the virus was 10.6% (95% CI 8.4%–13.0%); age-adjusted prevalence was 7.6%. Seropositivity was associated with age, Arab ethnicity, low socioeconomic status, and birth in Africa, Asia, or the former Soviet Union.

Acute viral hepatitis is caused by hepatitis E virus (HEV), which can be divided into 4 genotypes (14). Genotype 1, transmitted mainly through the fecal-oral route, is most common in developing countries in Asia, Africa, and Central America, where the disease is highly endemic. In industrialized countries, hepatitis E is infrequent, although in recent years, sporadic cases have been reported, resulting mainly from zoonotic transmission of HEV genotype 3 (13).

Prevalence rates of HEV IgG, a marker of previous exposure to HEV, range from 1% to 20% in industrialized countries (1). This marked variability in reported prevalence has been attributed to the use of different IgG assays with significantly different sensitivities (4).

The population of Israel comprises 2 major population groups, Jews (80%) and Arabs (including Muslims, Christians, and Druze); each has distinct cultural and socioeconomic features (5). In a study published in 1995, a low seroprevalence of anti-HEV antibodies in Israel was found among Jews (2.81%) and Arabs (1.81%) (6). These data were obtained by using an immunoassay developed 20 years ago; newer assays are considered more sensitive and specific to HEV IgG (4).

The Study

We used an age-stratified sampling design to systematically select 729 serum samples from those deposited during 2009–2010 at the National Serum Bank of the Israeli Center of Disease Control. Included were anonymous residual samples from diagnostic laboratories (403 samples) and from healthy blood donors (326 samples). Demographic information (place of birth, population group, and place of residence) was available for all donors. Socioeconomic status (SES) was assessed by the socioeconomic rank as defined by the Israel Central Bureau of Statistics; this system categorizes each place of residence on a 10-point scale based on parameters such as financial resources, housing density, motorization, education, and employment profile (7). Levels of HEV IgG were determined by using the DS-Anti-HEV-IgG kit (Diagnostic Systems Italy, Saronno, Italy), which is capable of detecting antibodies against all 4 HEV genotypes. Statistical analyses included χ2, t test, and univariate and multivariate logistic regression models to evaluate factors associated with hepatitis E infection. Odds ratios (OR) and 95% CI were calculated. A p value of <0.05 was considered statistically significant. Data were analyzed by using SAS version 9.1.3 (SAS Institute, Cary, NC, USA). This study was approved by the Institutional Review Board of Sheba Medical Center (approval no. 9927–12-SMC).

Of 729 samples, 77 (10.6%, 95% CI 8.4%–13.0%) tested positive for HEV IgG. The calculated age-adjusted prevalence rate for the population of Israel was 7.6%. Seropositivity increased significantly with age (Table 1); seroprevalence among persons >60 years of age was 37.5%, compared with 0.5% among those <20 years of age. HEV seropositivity, which was mainly observed in older persons, was significantly higher among Arabs (22.5%) compared with non-Arabs (10.3%). Among Jews, a significant association was found between samples testing positive for anti-HEV IgG and having been born in Africa (50%), Asia (53.8%), or the former Soviet Union (17.9%) compared with Israel (OR 10.4, 95% CI 6.1–17.9; p<0.0001) and also with an earlier year of immigration to Israel (OR 2.5, 95% CI 1.2–5.4; p = 0.02). The odds for testing HEV IgG–positive were highest among those of low SES (OR 2.9, 95% CI 1.4–5.9; p = 0.003). The multivariate logistic regression model also showed significant association between HEV seropositivity and advanced age, low SES, Arab ethnicity, and having been born in Asia, Africa, or the former Soviet Union (Table 2).

The prevalence of HEV antibodies we found is higher than previously reported in Israel and is consistent with other studies that have reported higher prevalence rates with the use of new, more sensitive immunoassays (4). Although it was argued that high prevalence of anti-HEV antibodies could be attributed to nonspecific or false-positive serum reactions (8), the low prevalence we found among those <40 years of age and the significant association between the prevalence of HEV antibodies and older age suggest that it is unlikely to be a result of nonspecific serum reactions.

Association of seropositivity with age was also reported in Denmark and the United Kingdom (9,10). Such associations could represent a cohort effect related to infection in the past or could be a result of ongoing low incidence of HEV infection resulting in cumulative exposure to infection over time. In Denmark, a statistically significant difference was detected in the overall HEV prevalence among samples from blood donors collected in 1983 versus those collected in 2003, suggesting that past exposure contributed to the anti-HEV response and that the prevalence of HEV seropositivity had decreased over the years (9). In contrast, in HEV-endemic countries, transmission might be ongoing; in India, the age-specific prevalence of anti-HEV did not change during 1982–1992 (11). Similarly, overall, 3.2% of blood donors in France were HEV-positive, but 52.5% of blood donors in southwest France, which includes the Midi-Pyrénées region, where HEV is endemic, were HEV positive (12).

No HEV outbreak has been documented in Israel; the total number of autochthonous HEV infections is unknown. Acute infections were reported only among travelers returning to Israel from HEV-endemic countries (13), further suggesting that ongoing transmission of HEV in Israel is unlikely.

Our findings that low SES is associated with HEV seropositivity is supported by others who have suggested low SES and poor environmental conditions are risk factors for HEV infection (14). The higher seropositivity observed among persons born in Africa, Asia, or the former Soviet Union corroborates with HEV endemicity and documented large outbreaks in these regions (3).

Although we found the seropositivity rate in the population of Israel to be higher than previously reported, and associated with specific population subgroups, this study has several limitations. Being a cross-sectional study, it is impossible to rule out recent or ongoing infections among older persons. To better address this issue, the presence of HEV RNA and anti HEV IgM antibodies, which together provide the most sensitive measure for acute infection, should be assessed in a much larger representative sample of older persons of all populations. Moreover, HEV genotype which was not addressed in this study should be determined in persons positive for HEV RNA. Because the prevalence of HEV infection in animals in Israel has not been documented, a study to better understand the HEV transmission root would be useful, especially because the consumption of pork, a common source of HEV infection, is religiously prohibited for both Arab Muslims and Jews (15).


The findings of this study indicate high numbers of past HEV infections among immigrants to Israel, which seemingly occurred in countries in which HEV is endemic. The higher HEV prevalence found among older persons in the Arab population, which was also associated with low SES, compared with the non-Arab population could be attributed to previous local exposure. The current overall HEV infection rate in Israel is low, as suggested both by the low prevalence in the younger population and the absence of any documented HEV outbreaks in Israel. However, the nature of this study cannot rule out ongoing infections among older persons. Surveillance of HEV through mandatory reporting of communicable diseases should continue to enable detection of emerging and reemerging infections.

Dr. Mor is the head of the Clinical Virology Laboratory and the director of the National HIV and Hepatitis Reference Laboratory in the MOH in Israel. Her research interests include HIV resistance in high and low viral load conditions and viral hepatitis.



We thank Diagnostic Systems Italy for providing 2 HEV IgG detection kits.



  1. Aggarwal  R, Hepatitis  E. Historical, contemporary and future perspectives. J Gastroenterol Hepatol. 2011;26(Suppl 1):72–82. PubMed DOI
  2. Dalton  HR, Hunter  JG, Bendall  RP, Hepatitis  E. Curr Opin Infect Dis. 2013;26:471–8. PubMed DOI
  3. Kamal  SM, Mahmoud  S, Hafez  T, El-Fouly  R. Viral hepatitis A to E in South mediterranean countries. Mediterr J Hematol Infect Dis. 2010;2:e2010001. PubMed DOI
  4. Pas  SD, Streefkerk  RH, Pronk  M, de Man  RA, Beersma  MF, Osterhaus  AD, Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol. Dec;58(4):629–34. PubMed http://dx.doi.org10.1016/j.jcv.2013.10.010
  5. Central Bureau of Statistics. Israel. Population. Statistical Abstracts of Israel, No. 64. 2013 [cited 11 Feb 2014].
  6. Karetnyi  YV, Favorov  MO, Khudyakova  NS, Weiss  P, Bar-Shani  S, Handsher  R, Serological evidence for hepatitis E virus infection in Israel. J Med Virol. 1995;45:316–20. PubMed DOI
  7. Central Bureau of Statistics. Israel. Society and welfare. Statistical abstracts of Israel, no. 64. 2013 [cited 11 Feb 2014];
  8. Olsen  B, Axelsson-Olsson  D, Thelin  A, Weiland  O. Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls. Scand J Infect Dis. 2006;38:55–8. PubMed DOI
  9. Christensen  PB, Engle  RE, Hjort  C, Homburg  KM, Vach  W, Georgsen  J, Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis. 2008;47:1026–31. PubMed DOI
  10. Dalton  HR, Stableforth  W, Thurairajah  P, Hazeldine  S, Remnarace  R, Usama  W, Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20:784–90. PubMed DOI
  11. Arankalle  VA, Tsarev  SA, Chadha  MS, Alling  DW, Emerson  SU, Banerjee  K, Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis. 1995;171:447–50. PubMed DOI
  12. Mansuy  JM, Bendall  R, Legrand-Abravanel  F, Saune  K, Miedouge  M, Ellis  V, Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis. 2011;17:2309–12. PubMed DOI
  13. Lachish  T, Tandlich  M, Schwartz  E. Acute hepatitis in Israeli travelers. J Travel Med. 2013;20:232–6. PubMed DOI
  14. Pourpongporn  P, Samransurp  K, Rojanasang  P, Wiwattanakul  S, Srisurapanon  S. The prevalence of anti-hepatitis E in occupational risk groups. [PubMed]. J Med Assoc Thai. 2009;92(Suppl 3):S3842.PubMed
  15. Pappas  G. Socio-economic, industrial and cultural parameters of pig-borne infections. Clin Microbiol Infect. 2013;19:605–10. PubMed DOI




Cite This Article

DOI: 10.3201/eid2104.140245

Table of Contents – Volume 21, Number 4—April 2015

Page created: March 17, 2015
Page updated: March 17, 2015
Page reviewed: March 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.